

Data Sheet

Product Information

Catalog Number	BP10145
Product Name	Sitravatinib
Description	Sitravatinib (MGCD516) is an inhibitor targeting multiple RTKs involved in driving sarcoma cell growth, including c- Met, c-Kit, PDGFRα/β, PDGFR, and Axl.
Targets&IC50	DDR2: 0.5 nM, EPHA3: 1 nM, Mer: 2 nM, VEGFR3 (FLT4): 2 nM, Axl: 1.5 nM
In vitro	Cell lines: DDLS,LS141,and MPNST. Concentrations: 62.5,125,250,500,1000,2000 nM2,000-3,000 cells were plated in 96-well plates in RPMI/DME media with 10% FBS and then treated with the indicated drugs the next day.After 72 hours,media was replaced with 100 μ L of media with 10% serum and 10% CCK-8 solution.After 1 hour,the optical density was read at 450 nm to determine viability.Background values from negative control wells without cells were subtracted for final sample quantification.Data was plotted as % cell viability compared to DMSO control.
In vivo	Animal Models: ICR/SCID mice. Formulation: 0.5% hydroxypropyl methylcellulose (HPMC) and 0.1% Tween-80 solution (pH 1.4). Dosages: 15 mg/kg. Administration: p.o.
Synonyms	MG516, MGCD516
CAS No.	1123837-84-2
Chemical Formula	C33H29F2N5O4S
Molecular Weight	629.68
Solubility	DMSO: 32 mg/mL

Storage	Powder: -20°C for 2 years In solvent: -80°C for 1 year
Chemical Structure OR Tested Image	
Purdue Bioscience Inc.	
750 50th St, Brooklyn, NY 11220, USA	
https://www.purduebio.com	
1-877.618.7311	
info@purduebio.com	
v2 Revision on 12/28/2022	

v2 Revision on 12/28/2022 euroue e